FDA Alert – Oral Nizoral (ketoconazole): Unapproved Use Continues, Linked to Patient Death

Information sourced from FDA:

Nizoral (ketoconazole) Oral Tablets: Drug Safety Communication - Prescribing for Unapproved Uses including Skin and Nail Infections Continues; Linked to Patient Death

ISSUE: FDA is warning health care professionals to avoid prescribing the antifungal medicine ketoconazole oral tablets to treat skin and nail fungal infections. Use of this medication carries the risk of serious liver damage, adrenal gland problems, and harmful interactions with other medicines that outweigh its benefit in treating these conditions, which are not approved uses of the drug.

FDA approved label changes for oral ketoconazole tablets in 2013 to reflect these serious risks and to remove the indications for treatment of skin and nail fungal infections. However, an FDA safety review found that oral ketoconazole continues to be prescribed for these types of conditions. Since the 2013 labeling change, one patient death has been reported to the FDA due to liver failure associated with oral ketoconazole prescribed to treat a fungal infection of the nails. See the full Drug Safety Communication for further information.

BACKGROUND: Ketoconazole in tablet form is indicated to treat serious infections caused by fungi and should be used only when other effective therapy is not available or tolerated. It works by killing the fungus or preventing it from growing. The topical forms of ketoconazole that are applied to the skin or nails have not been associated with liver damage, adrenal problems, or drug interactions.

In a July 2013 Drug Safety Communication, FDA warned that ketoconazole tablets should not be used as a first-line treatment for any fungal infection because it can cause severe liver injury and adrenal gland problems, and advised it can lead to harmful interactions with other medicines. FDA determined that the risks outweigh the benefits for treating skin and nail fungal infections and approved label changes removing this indication from the drug label and limited its labeled indication to treating only serious fungal infections.

RECOMMENDATION: Health care professionals should use ketoconazole tablets only to treat serious fungal infections when no other antifungal therapies are available. Skin and nail fungal infections in otherwise healthy persons are not life-threatening, and so the risks associated with oral ketoconazole outweigh the benefits. Other treatment options are available over-the-counter and by prescription, but are also associated with risks that should be weighed against their benefits.

Patients should discuss with their health care professionals the risks and benefits of available therapies before using any medicine to treat skin and nail fungal infections. Patients taking ketoconazole tablets should seek medical attention right away if they experience any of these signs and symptoms of liver problems, which include loss of appetite, nausea, vomiting, or abdominal discomfort; yellowing of the skin or the whites of the eyes (jaundice); unusual darkening of the urine or lightening of the stools; or pain and discomfort in the right upper abdomen where the liver is located.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:

Complete and submit the report Online: www.fda.gov/MedWatch/report
Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Comments

Post a Comment

Cool

Popular posts from this blog

10 EARLY PREGNANCY SYMPTOMS WHICH APPEAR BEFORE MISSING A PERIOD

Many women experience the first pregnancy symptoms days before missing a period as a result of the shift in the hormones, which causes certain changes in the body. The first pregnancy symptoms can occur up to a week before a sufficient number of pregnancy hormones starts to circulate in the body to give a positive result on the pregnancy test. Here are the earliest symptoms of pregnancy, which appear before a missed period. Pregnancy Symptoms Cramping Cramping is one of the earliest symptoms of pregnancy. The cramps can be noticed when your embryo implants into your uterus. This sign can be easily mistaken for menstrual cramps. Fatigue Increased levels of progesterone can make you feel exhausted. Fatigue is usually experienced as early as a week after ovulation. After you ovulate, the levels of progesterone rise, regardless of being pregnant or not. However, if you are not pregnant your progesterone levels will soon decrease. After ovulation, if you start feeling tired, and if t...
Read more

First Birth Control For Men, An Injection To The Groin, Will Be Available Soon

The use of contraceptives has been largely associated with women, but birth control for men might soon be available for use after Indian scientists announced that they have successfully completed clinical trials on the world’s first male birth control injection. The Indian Council for Medical Research said that the “product is ready,” and has a 97.3% success rate with no side effects, according to a report from the Hindustan Times. The contraceptive works via an injection to the vas deferens, the sperm-containing tube near the testicles. It contains a polymer called Steryene Maleic Anhydride, which was developed in the 1970s to inhibit sperm production. According to the report, the contraceptive will be effective for 13 years. VG Somani, the Drug Controller General of India, estimates approval of the drug to take around six months, minimum. “It’s the first in the world from India so we have to be extra careful about approval. We are looking at all aspects, especiall...
Read more

Novartis sickle-cell drug gets U.S. FDA approval

By John Miller and Carl O’Donnell (Reuters) - Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance. The drug will be priced between $84,852 and $113,136 per year for most patients, who will be infused by a healthcare provider with between three and four vials each month, Novartis said. The biologic drug, also known as crizanlizumab, was shown in trials in its high-dose formula to cut sickle cell pain crises nearly by half to 1.63 incidents annually from 2.98 in those getting a placebo. The Food and Drug Administration’s approval came nearly two months ahead of its due date for a decision in January. Novartis has forecast that the drug’s annual sales will top $1 billion, much of which will likely come from U.S. government payers such as Medicare and Medicaid. The dru...
Read more